Boasso Adriano
>Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. Tel.: +44 208 746 5993; ;
HIV Ther. 2009 May;3(3):269-282. doi: 10.2217/hiv.09.8. Epub 2009 Apr 30.
Type I interferons (IFNs) are soluble molecules that exert potent antiviral activity and are currently used for the treatment of a panel of viral infections. In the case of HIV, the use of type I IFN has had limited success, and has almost been abandoned. During the last decade, a series of studies has highlighted how HIV infection may cause overactivation of type I IFN production, which contributes to the exhaustion of the immune system and to disease progression. This review describes the transition from the proposed use of type I IFN as antiviral drugs in HIV infection, to the idea that blocking their activity or production may provide an immunologic benefit of much greater importance than their antiviral activity.
I型干扰素（IFNs）是具有强大抗病毒活性的可溶性分子，目前用于治疗一系列病毒感染。就HIV而言，I型干扰素的使用成效有限，几乎已被弃用。在过去十年中，一系列研究突出了HIV感染如何可能导致I型干扰素产生的过度激活，这会导致免疫系统耗竭和疾病进展。这篇综述描述了从提议将I型干扰素用作HIV感染的抗病毒药物，到认为阻断其活性或产生可能带来比其抗病毒活性重要得多的免疫益处这一转变。
